Stockscreener 앱 받기
9.04
5.44%
-0.52
시간 외 거래:
9.04
전일 마감가:
$9.56
열려 있는:
$9.43
하루 거래량:
143.37K
Relative Volume:
1.32
시가총액:
$406.02M
수익:
$239.40M
순이익/손실:
$104.44M
주가수익비율:
3.0541
EPS:
2.96
순현금흐름:
$-18.50M
1주 성능:
-16.30%
1개월 성능:
-24.29%
6개월 성능:
-43.43%
1년 성능:
-36.20%
1일 변동 폭
$8.85
$9.43
1주일 범위
$8.85
$10.87
52주 변동 폭
$8.85
$21.79
Entrada Therapeutics Inc Stock (TRDA) Company Profile
명칭
Entrada Therapeutics Inc
전화
857-305-1825
주소
ONE DESIGN CENTER PLACE, BOSTON
TRDA을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
TRDA
Entrada Therapeutics Inc
|
9.04 | 406.02M | 239.40M | 104.44M | -18.50M | 2.96 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.82 | 131.41B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
634.23 | 72.26B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
591.87 | 36.10B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
270.02 | 35.03B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
272.17 | 28.24B | 3.81B | -644.79M | -669.77M | -6.24 |
Entrada Therapeutics Inc Stock (TRDA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-12-06 | 개시 | ROTH MKM | Buy |
| 2024-01-05 | 개시 | Oppenheimer | Outperform |
| 2023-04-03 | 개시 | H.C. Wainwright | Buy |
Entrada Therapeutics Inc 주식(TRDA)의 최신 뉴스
Entrada Therapeutics Gains Momentum Amid Exon-Skipping Advances and Regulatory Approvals - TipRanks
Entrada Therapeutics stock rating holds with $20 target By Investing.com - Investing.com UK
Entrada Therapeutics stock hits 52-week low at $9.74 By Investing.com - Investing.com UK
Charles Schwab Investment Management Inc. Boosts Holdings in Entrada Therapeutics, Inc. (NASDAQ:TRDA) - Defense World
Roth/MKM maintains Buy on Entrada stock, $23 target By Investing.com - Investing.com Canada
Positive Outlook on Entrada Therapeutics Inc Due to Promising Developments in Duchenne Muscular Dystrophy Treatment - TipRanks
Entrada Therapeutics gets approval to start trial of its DMD treatment in the UK (TRDA:NASDAQ) - Seeking Alpha
Entrada Therapeutics rises on UK approval for muscle-wasting drug study - TradingView
Entrada’s ENTR-601-45 gains clearance in UK to enter clinic for Duchenne muscular dystrophy - BioWorld MedTech
Entrada Therapeutics begins Duchenne study in UK By Investing.com - Investing.com Australia
Entrada Therapeutics begins Duchenne study in UK - Investing.com India
Entrada Therapeutics Gains UK Approval for DMD Study - TipRanks
Entrada Therapeutics Receives Authorization in the United Kingdom to Initiate ELEVATE-45-201, a Phase 1/2 Multiple Ascending Dose Clinical Study of ENTR-601-45 in People Living with Duchenne Muscular Dystrophy Amenable to Exon 45 Skipping - The Manila Times
Major Breakthrough: Entrada's DMD Drug Gets Green Light for UK Clinical Trials - Stock Titan
Bank of New York Mellon Corp Lowers Stock Position in Entrada Therapeutics, Inc. (NASDAQ:TRDA) - Defense World
Entrada Therapeutics stock hits 52-week low at $10.21 - Investing.com
Entrada Therapeutics CFO sells $19,035 in stock By Investing.com - Investing.com South Africa
Entrada Therapeutics CFO sells $19,035 in stock - Investing.com India
Long Term Trading Analysis for (TRDA) - news.stocktradersdaily.com
Entrada Therapeutics stock hits 52-week low at $10.25 By Investing.com - Investing.com Australia
Entrada Therapeutics stock hits 52-week low at $10.25 - Investing.com
Entrada Therapeutics (TRDA) Expected to Announce Earnings on Wednesday - Defense World
Entrada Therapeutics stock hits 52-week low at $11.3 amid market shifts - Investing.com Canada
Brokers Offer Predictions for TRDA Q4 Earnings - Defense World
What is William Blair’s Estimate for TRDA Q1 Earnings? - Defense World
Results: Entrada Therapeutics, Inc. Beat Earnings Expectations And Analysts Now Have New Forecasts - simplywall.st
Entrada Therapeutics, Inc. Just Beat EPS By 55%: Here's What Analysts Think Will Happen Next - Yahoo Finance
Entrada Therapeutics (NASDAQ:TRDA) Releases Earnings Results, Beats Estimates By $0.69 EPS - MarketBeat
Entrada Therapeutics' (TRDA) Buy Rating Reiterated at HC Wainwright - MarketBeat
Entrada Therapeutics: Regulatory Progress and Strategic Trials Drive Buy Rating - TipRanks
Entrada Therapeutics reports Q4 EPS 3c vs. (29c) last year - TipRanks
Oppenheimer maintains Entrada stock Outperform with $30 target - Investing.com
Oppenheimer maintains Entrada stock Outperform with $30 target By Investing.com - Investing.com South Africa
Entrada Therapeutics Reports Strong 2024 Financial Results - TipRanks
Entrada Therapeutics earnings beat by $0.70, revenue fell short of estimates - Investing.com UK
Entrada Therapeutics sees cash runway into 2Q27 - TipRanks
Entrada Therapeutics, Inc. SEC 10-K Report - TradingView
Entrada Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results - The Manila Times
HC Wainwright Reiterates Buy Rating for Entrada Therapeutics (NASDAQ:TRDA) - Defense World
Allspring Global Investments Holdings LLC Lowers Stake in Entrada Therapeutics, Inc. (NASDAQ:TRDA) - Defense World
Entrada Therapeutics Receives Buy Rating Amid Regulatory Progress and Promising Clinical Developments - TipRanks
FDA authorizes Entrada’s DMD drug study By Investing.com - Investing.com Australia
Optimistic Outlook on Entrada Therapeutics: FDA Lifts Hold on ENTR-601-44, Paving Way for Key Trials - TipRanks
FDA Clears Entrada Therapeutics' Early-Stage For Potential Treatment Of Duchenne Muscular Dystrophy - Benzinga
Entrada Therapeutics Says FDA Lifted Clinical Hold on ENTR-601-44; Shares Advance Premarket - Marketscreener.com
Entrada rises as FDA removes clinical hold on muscle-wasting therapy - TradingView
FDA authorizes Entrada's DMD drug study - Investing.com India
FDA authorizes Entrada’s DMD drug study - Investing.com
Entrada Therapeutics Receives FDA Approval for DMD Study - TipRanks
FDA authorizes Entrada's DMD drug study By Investing.com - Investing.com South Africa
Entrada Therapeutics Announces FDA Removal of Clinical Hold on ENTR-601-44 - The Manila Times
Entrada Therapeutics Inc (TRDA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.05%
1.79%
자본화:
|
볼륨(24시간):